+91-95913-21052
enquiries@prajeeva.com
Book
Consultation
Your Gut Contains 38 Trillion Microbes.
Most People Have Never Had Them Properly Analysed.
Prajeeva offers gut microbiome testing through BugSpeaks®, South Asia’s first gut microbiome testing platform and one of India’s leading clinical microbiome testing services, developed by Bengaluru-based Leucine Rich Bio Pvt Ltd. BugSpeaks® uses full shotgun metagenomic sequencing — a technology that identifies microbes at species and strain level, not merely genus level — and references results against Indian population datasets built through systematic testing since 2014. Results are interpreted by Prajeeva physicians within the context of your clinical history, conventional laboratory investigations, and health goals.
Why The Gut Microbiome
Is A Clinical Priority
Research over the past decade has substantially expanded understanding of the gut microbiome’s role in health and disease. A substantial proportion of the body’s immune cells reside within the gut-associated lymphoid tissue (GALT), and the intestinal microbiome plays an important role in modulating immune responses.
Short-chain fatty acids (SCFAs) — particularly butyrate, propionate and acetate — produced through microbial fermentation of dietary fibre, serve as important energy substrates for colonocytes and have been associated with intestinal barrier integrity and systemic metabolic effects in research studies. The gut-brain axis — a bidirectional communication network involving neural, hormonal and immunological pathways — is an active area of scientific inquiry with emerging clinical implications.
Gut microbiome diversity has been associated with metabolic health, immune function, and resilience to gastrointestinal disease in multiple epidemiological studies. A 2024 published clinical trial by BugSpeaks® reported improvements in glycaemic and inflammatory parameters following microbiome-guided personalised nutrition — supporting the clinical utility of physician-interpreted microbiome analysis.
Standard blood tests do not assess the gut microbiome. A comprehensive metabolic panel may be entirely unremarkable in a patient whose microbiome composition is contributing to presenting symptoms. Gut microbiome analysis provides a complementary layer of clinical information that conventional investigations do not capture.
Explore Advanced Diagnostics & Biomarker Analysis
Why BugSpeaks® -
Technology and Accreditation
Not all gut microbiome tests are equivalent. The technology used determines both the depth of microbial identification and the reliability of the analysis. BugSpeaks® was selected by Prajeeva because of three specific advantages.
Advantage
Details
Full Shotgun Metagenomics (not 16S rRNA)
BugSpeaks® uses full shotgun metagenomic sequencing of the entire microbial DNA present in the stool sample. Unlike 16S rRNA-based tests, which identify only bacteria and archaea at genus level, shotgun metagenomics identifies bacteria, archaea, fungi, viruses and other microbes at species and strain level — providing substantially greater resolution and clinical information.
Indian Population Reference Datasets
India’s microbiome exhibits high variability due to regional diets, climate, genetics, and hygiene patterns that differ substantially from Western populations. BugSpeaks® has built one of the largest gut microbiome repositories in South Asia through systematic testing since 2014. Results are referenced against this dataset, producing interpretations that are relevant to Indian gut ecology rather than extrapolated from European or American cohorts.
Accreditation And Clinical Validation
BugSpeaks® is NABL, NABH, ISO 9001:2015 and ISO/IEC 17025:2017 accredited. A 2024 randomised clinical study published by the BugSpeaks® team reported improvements in glycaemic and inflammatory parameters following microbiome-guided dietary protocols — one of the few Indian microbiome platforms with published clinical outcome data.
Prajeeva’s clinical team interprets every BugSpeaks® report in the context of the patient’s full clinical picture rather than as a standalone result.
Speak With Our Medical TeamWhat The
Report Includes?
The BugSpeaks® gut microbiome report provides a structured analysis of microbial composition and actionable recommendations. These findings may help physicians understand mechanisms that may contribute to gastrointestinal and systemic health. They are adjunctive and require interpretation alongside conventional clinical and laboratory assessment.
Report Domain
What It Describes?
Taxonomic Composition
Identification and relative abundance of bacterial, archaeal, fungal and viral species present in the gut sample at species and strain level — a level of resolution not achievable with 16S rRNA methods.
Microbial Diversity
Species richness and compositional balance of the microbial community, referenced against BugSpeaks®’s Indian population dataset. Low diversity has been associated with multiple gastrointestinal and metabolic conditions in the scientific literature.
Species Abundance
Relative proportions of key bacterial phyla and clinically significant species. Includes Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria, and genus- and species-level findings with clinical context.
Beneficial Microbes
Presence and relative abundance of microorganisms associated with favourable health outcomes in the research literature, such as Akkermansia muciniphila, Faecalibacterium prausnitzii, and Bifidobacterium species.
The BugSpeaks® report describes microbiome associations and provides clinical context. It does not independently diagnose gastrointestinal or systemic disease, and does not directly measure inflammation, intestinal permeability, or biological ageing. All findings are adjunctive and require physician interpretation alongside clinical history and conventional laboratory investigations.
Speak With Our Medical TeamWho May Benefit From
Gut Microbiome Testing
-
Bloating, IBS, Irregular Bowel, Food Intolerances
Dysbiosis patterns, relative abundance of opportunistic organisms, and low microbial diversity that may provide clinical context for gastrointestinal symptom management.
-
Chronic Fatigue And Impaired Recovery
Reduced relative abundance of SCFA-producing bacteria, which may be relevant to intestinal barrier function and gut-brain axis signalling as described in the research literature.
-
Metabolic Syndrome, Insulin Resistance, Weight Management
Microbial compositional patterns including Akkermansia muciniphila abundance have been associated with metabolic parameters in research studies.
-
Mood And Sleep Disturbance
Gut-brain axis research has identified associations between microbiome composition and mood-relevant biological pathways. These findings provide clinical context, not diagnostic conclusions.
-
Autoimmune And Chronic Inflammatory Conditions
Relative abundance of protective species such as Faecalibacterium prausnitzii and the presence of opportunistic organisms may provide supporting information for inflammatory condition management alongside conventional care.
-
Post-Antibiotic Or Post-Illness Recovery
Diversity collapse following antibiotic treatment or significant illness is well-documented. The report provides a compositional picture to guide restorative dietary, prebiotic, and probiotic strategies.
-
Preventive And Longevity Programme Participants
Microbiome diversity is an emerging metric in healthy ageing research. Baseline and repeat profiling supports long-term monitoring of gut health within the Prajeeva longevity programme.
How Gut Microbiome Testing
Works at Prajeeva
Clinical Note : Gut microbiome testing is an adjunctive investigation and does not independently diagnose gastrointestinal or systemic disease. Results should always be interpreted by a physician alongside clinical history, physical examination, and conventional laboratory investigations. Microbiome science is a rapidly evolving field and the associations described in the report reflect the current evidence base, which continues to develop.
